肿瘤浸润甲状腺外组织提示V区淋巴结转移风险

2012-07-04 张辉摘编 医学论坛网

  四川大学华西医院普外科陈锐、魏涛等的一项研究表明,肿瘤浸润甲状腺外组织及同侧Ⅱ、Ⅲ、Ⅳ区淋巴结同时转移是甲状腺乳头状癌患者Ⅴ区淋巴结转移的危险因素,对于这一类患者建议行Ⅴ区淋巴结清扫。该论文发表在2012年第7期《中华外科杂志》。   研究人员回顾性分析2004年3月至2010年11月资料完整的122例甲状腺乳头状癌患者的临床病理资料。其中男性31例,女性91例;中位年龄38.5岁。每个病例

  四川大学华西医院普外科陈锐、魏涛等的一项研究表明,肿瘤浸润甲状腺外组织及同侧Ⅱ、Ⅲ、Ⅳ区淋巴结同时转移是甲状腺乳头状癌患者Ⅴ区淋巴结转移的危险因素,对于这一类患者建议行Ⅴ区淋巴结清扫。该论文发表在2012年第7期《中华外科杂志》。

  研究人员回顾性分析2004年3月至2010年11月资料完整的122例甲状腺乳头状癌患者的临床病理资料。其中男性31例,女性91例;中位年龄38.5岁。每个病例至少行一侧Ⅱ~Ⅵ区颈淋巴结清扫术,13例行Ⅰ~Ⅵ区颈淋巴结清扫术,19例行双侧颈淋巴结清扫术。用χ2检验对患者年龄、性别、术前远处转移、术后TNM分期、原发灶大小、癌灶多发、肿瘤浸润情况、中央区及同侧Ⅱ~Ⅳ区淋巴结转移情况与Ⅴ区淋巴结转移进行单因素分析,用二分类Logistic回归对单因素分析中有统计学意义的指标进行多因素分析。

  结果显示,甲状腺乳头状癌患者Ⅴ区淋巴结转移组与未转移组在年龄、性别、癌灶多发、中央区淋巴结转移、同侧Ⅱ区淋巴结转移、同侧Ⅲ区淋巴结转移及术后TNM分期等因素比较中差异无统计学意义(P>0.05),而在肿瘤浸润被膜、浸润甲状腺外组织、术前远处转移、原发灶>4.0 cm、同侧Ⅳ区淋巴结转移及同侧Ⅱ、Ⅲ、Ⅳ区淋巴结同时转移等因素中差异有统计学意义(P<0.05)。多因素分析显示,肿瘤浸润甲状腺外组织(P=0.001)和同侧Ⅱ、Ⅲ、Ⅳ区淋巴结同时转移(P=0.002)是Ⅴ区淋巴结转移的高危因素。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813698, encodeId=67ed18136988e, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 12 23:41:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292919, encodeId=375d1292919a7, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jul 06 06:41:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302486, encodeId=8443130248658, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jul 06 06:41:00 CST 2012, time=2012-07-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813698, encodeId=67ed18136988e, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 12 23:41:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292919, encodeId=375d1292919a7, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jul 06 06:41:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302486, encodeId=8443130248658, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jul 06 06:41:00 CST 2012, time=2012-07-06, status=1, ipAttribution=)]
    2012-07-06 sodoo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813698, encodeId=67ed18136988e, content=<a href='/topic/show?id=f6319345919' target=_blank style='color:#2F92EE;'>#转移风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93459, encryptionId=f6319345919, topicName=转移风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Feb 12 23:41:00 CST 2013, time=2013-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292919, encodeId=375d1292919a7, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Jul 06 06:41:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302486, encodeId=8443130248658, content=<a href='/topic/show?id=7be06602886' target=_blank style='color:#2F92EE;'>#淋巴结转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66028, encryptionId=7be06602886, topicName=淋巴结转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Jul 06 06:41:00 CST 2012, time=2012-07-06, status=1, ipAttribution=)]